Monopar Therapeutics (MNPR) Assets Average (2018 - 2025)

Monopar Therapeutics (MNPR) has 8 years of Assets Average data on file, last reported at $142.5 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average rose 329.34% year-over-year to $142.5 million; the trailing twelve-month figure through Dec 2025 stood at $142.5 million (up 329.34% YoY), and the FY2025 full-year result was $100.5 million, up 197.19% from the prior year.
• Assets Average rose to $142.5 million in Q4 2025, from $99.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $142.5 million in Q4 2025 to a low of $6.6 million in Q3 2024.
• A 5-year average of $30.4 million and a median of $18.3 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 42.4% in 2023 and surged 1394.88% in 2025, its largest moves.
• Tracing MNPR's Assets Average over 5 years: stood at $21.5 million in 2021, then sank by 35.7% to $13.8 million in 2022, then plunged by 42.4% to $8.0 million in 2023, then surged by 316.36% to $33.2 million in 2024, then jumped by 329.34% to $142.5 million in 2025.
• Business Quant data shows MNPR's Assets Average at $142.5 million in Q4 2025, $99.0 million in Q3 2025, and $54.5 million in Q2 2025.